ATE429645T1 - Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten - Google Patents
Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheitenInfo
- Publication number
- ATE429645T1 ATE429645T1 AT05811604T AT05811604T ATE429645T1 AT E429645 T1 ATE429645 T1 AT E429645T1 AT 05811604 T AT05811604 T AT 05811604T AT 05811604 T AT05811604 T AT 05811604T AT E429645 T1 ATE429645 T1 AT E429645T1
- Authority
- AT
- Austria
- Prior art keywords
- neurodegenerative diseases
- eph receptor
- receptor inhibitors
- treat neurodegenerative
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108091008815 Eph receptors Proteins 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 abstract 1
- 102000050554 Eph Family Receptors Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04028046A EP1662259A1 (de) | 2004-11-25 | 2004-11-25 | Verwendung von Eph Rezeptor-Inhibitoren zur Behandlung von neurodegenerativen Erkrankungen |
| US63059204P | 2004-11-26 | 2004-11-26 | |
| PCT/EP2005/012649 WO2006056467A1 (en) | 2004-11-25 | 2005-11-25 | Use of eph receptor inhibitors for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429645T1 true ATE429645T1 (de) | 2009-05-15 |
Family
ID=34927535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05811604T ATE429645T1 (de) | 2004-11-25 | 2005-11-25 | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080213250A1 (de) |
| EP (2) | EP1662259A1 (de) |
| AT (1) | ATE429645T1 (de) |
| CA (1) | CA2589173A1 (de) |
| DE (1) | DE602005014134D1 (de) |
| WO (1) | WO2006056467A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888648A2 (de) * | 2005-06-03 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Verfahren zur behandlung, zur diagnose bzw. zum nachweis von krebs |
| EP2484782B1 (de) | 2006-01-05 | 2015-11-18 | The Ohio State University Research Foundation | Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von soliden Krebs |
| EP2369013A1 (de) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese |
| ES2318616T3 (es) * | 2006-06-01 | 2009-05-01 | Cellzome Ag | Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70. |
| GB0624689D0 (en) * | 2006-12-11 | 2007-01-17 | Glaxo Group Ltd | Novel fluorescent kinase ligands and methods employing the same |
| CA2680589A1 (en) | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano - Bicocca | Modulator compounds of the drug resistance in epithelial tumour cells |
| WO2008150010A1 (ja) | 2007-06-08 | 2008-12-11 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 |
| EP2177623A4 (de) * | 2007-07-19 | 2010-12-29 | Eisai R&D Man Co Ltd | SCREENINGVERFAHREN MIT c-MET, EINEM NEUEN SUBSTRAT FÜR GAMMA-SEKRETASE |
| EP2192181A4 (de) * | 2007-08-01 | 2010-12-08 | Eisai R&D Man Co Ltd | Screening-verfahren mit nutzung des neuen substrats c-ret für gamma-sekretase |
| EP2173908B1 (de) | 2007-08-03 | 2016-01-06 | The Ohio State University Research Foundation | Ultrakonservierte bereiche zur kodierung von ncrnas |
| CA2926831A1 (en) * | 2007-08-22 | 2009-02-26 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| JP5580598B2 (ja) * | 2007-11-15 | 2014-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | γ−セクレターゼの新規基質ＥｐｈＡ７を利用したスクリーニング方法 |
| EP2223999B1 (de) * | 2007-11-30 | 2017-10-18 | Eisai R&D Management Co., Ltd. | Epha4-polypeptid mit neuartiger aktivität und verwendung davon |
| US20100197688A1 (en) * | 2008-05-29 | 2010-08-05 | Nantermet Philippe G | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2009150513A2 (en) * | 2008-06-09 | 2009-12-17 | Oxford Biotherapeutics Ltd. | Protein |
| WO2010114921A1 (en) * | 2009-04-02 | 2010-10-07 | Burnham Institute For Medical Research | Eph receptor ligands and methods of use |
| WO2010141974A1 (en) * | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| US8159780B2 (en) | 2009-07-15 | 2012-04-17 | Seagate Technology Llc | Recording head heater systems with two electrical connections |
| KR20120082906A (ko) | 2009-09-30 | 2012-07-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법 |
| CN103648505B (zh) | 2010-11-12 | 2016-09-28 | 俄亥俄州立大学研究基金会 | 与微rna-21、错配修复和结肠直肠癌相关的材料和方法 |
| WO2012067839A2 (en) * | 2010-11-15 | 2012-05-24 | The J. David Gladstone Institutes | Methods of treating neurodegenerative disease |
| BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
| EP2653552B1 (de) | 2010-12-17 | 2016-10-19 | Eisai R&D Management Co., Ltd. | Screeningverfahren als index mit epha4-spaltungsreaktion durch gelatinase |
| US9784751B2 (en) | 2011-04-25 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain |
| EP2766500A4 (de) | 2011-10-14 | 2015-10-14 | Univ Ohio State | Verfahren und materialien in verbindung mit eierstockkrebs |
| CA2859430A1 (en) | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| CA2989993A1 (en) * | 2015-09-08 | 2017-03-16 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| EP3995582B1 (de) | 2019-07-01 | 2026-04-22 | Eisai R&D Management Co., Ltd. | Anti-epha4-antikörper |
| TW202330615A (zh) * | 2021-11-22 | 2023-08-01 | 中國醫藥大學 | Ｅｐｈｒｉｎ ａ型受體１０特異性抗體、表現其之嵌合抗原受體ｔ細胞及其應用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042100A1 (en) * | 1998-02-23 | 1999-08-26 | Sagami Chemical Research Center | Cell death inhibitors |
| GB9828640D0 (en) * | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| EP1469810A4 (de) * | 2002-01-04 | 2009-01-14 | Univ Rockefeller | Zusammensetzungen und verfahren zur verhütung und behandlung von erkrankungen im zusammenhang mit amyloid-beta peptid |
| RU2004135382A (ru) * | 2002-06-05 | 2005-06-27 | Янссен Фармацевтика Н.В. (Be) | Замещенные пирролины в качестве ингибиторов киназы |
| WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
-
2004
- 2004-11-25 EP EP04028046A patent/EP1662259A1/de not_active Withdrawn
-
2005
- 2005-11-25 WO PCT/EP2005/012649 patent/WO2006056467A1/en not_active Ceased
- 2005-11-25 EP EP05811604A patent/EP1815255B1/de not_active Expired - Lifetime
- 2005-11-25 CA CA002589173A patent/CA2589173A1/en not_active Abandoned
- 2005-11-25 US US11/791,289 patent/US20080213250A1/en not_active Abandoned
- 2005-11-25 DE DE602005014134T patent/DE602005014134D1/de not_active Expired - Fee Related
- 2005-11-25 AT AT05811604T patent/ATE429645T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006056467A1 (en) | 2006-06-01 |
| US20080213250A1 (en) | 2008-09-04 |
| EP1815255B1 (de) | 2009-04-22 |
| CA2589173A1 (en) | 2006-06-01 |
| EP1662259A1 (de) | 2006-05-31 |
| EP1815255A1 (de) | 2007-08-08 |
| DE602005014134D1 (de) | 2009-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005014134D1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
| NL301145I2 (nl) | Tirbanibulin | |
| MX2010002674A (es) | Moduladores de gamma secretasa. | |
| EA200970403A1 (ru) | Бициклические триазолы в качестве модуляторов протеинкиназы | |
| MX2010006379A (es) | Moduladores de la secretasa gamma. | |
| MX2010005028A (es) | Moduladores de gamma secretasa. | |
| DE602006019560D1 (de) | 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen | |
| ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| TNSN07027A1 (en) | Pyrrolo-pyridine kinase modulators | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| MX2008006076A (es) | Metodos, composiciones y kits para el tratamiento de condiciones medicas. | |
| NO20071272L (no) | Modulatorer av muskarine reseptorer. | |
| ATE512948T1 (de) | Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen | |
| EP1732484A4 (de) | Ophthalmisches implantat zur behandlung von glaukom | |
| ATE525372T1 (de) | Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen | |
| ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
| ATE421501T1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
| NO20073369L (no) | Modulatorer av muskarinreseptorer | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| ATE423110T1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
| EP4149464A4 (de) | Thiolhaltige verbindungen zur verwendung bei der behandlung von coronavirus | |
| ATE542535T1 (de) | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten | |
| WO2010147969A3 (en) | Gamma secretase modulators | |
| MX2010001501A (es) | Moduladores de gamma secretasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |